NetEase Shares Rise After Major Title Approved for Mobile Ahead of Earnings
By Tracy Qu
NetEase shares rose sharply in Hong Kong after the mobile version of its blockbuster PC title game was approved, fuelling expectations of strong earnings this year.
Shares rose 5.5% to hit 178.30 Hong Kong dollars (US$22.80) at the midday break Wednesday, taking their year-to-date gain to 26.8%. The company's U.S.-listed ADRs rose 5.3% in overnight trade.
China's National Press and Publication Administration on Tuesday approved more than 100 titles for February, adding to NetEase's game portfolio.
The market was particularly enthusiastic about the approval of the mobile version of NetEase's blockbuster PC title Naraka Bladepoint. The game, launched in 2021, is one of the best-selling Chinese PC games with a global presence in countries such as the U.S. and Japan.
Naraka Bladepoint's mobile version and other new launches will likely be the "key drivers in 2024", HSBC analysts Ritchie Sun and Charlene Liu said in a note.
Naraka Bladepoint's PC version was well received by players and named a Top Seller on the Steam gaming platform's Best of 2021 games list, NetEase said in its 2022 annual report.
The regulatory approval comes ahead of NetEase's fourth quarter results due Thursday and analysts are expecting the company to post strong earnings due to the robust performance of video games such as Justice Mobile and Eggy Party.
Write to Tracy Qu at tracy.qu@wsj.com
(END) Dow Jones Newswires
February 28, 2024 00:10 ET (05:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth